The Alliance for Regenerative Medicine Releases Agenda for 2017 Cell & Gene Meeting on the Mesa

WASHINGTON, DC--(Marketwired - Sep 6, 2017) - The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector, today released the agenda for its upcoming three-day Cell & Gene Meeting on the Mesa annual conference, October 4-6, 2017.

Organized by ARM and the UC San Diego Sanford Stem Cell Clinical Center, the Cell & Gene Meeting on the Mesa is three-day conference featuring three distinct parts: the program's two-day Partnering Forum, a Public Forum lecture and a full-day Scientific Symposium.

The event's Partnering Forum, held this year on October 4-5, features more than 90 speakers, presenting on the most pressing sector issues and focus areas in a variety of expert-led plenary sessions, featured talks, panels and workshops, including:

Plenary Session:

• Implications of CAR-T Commercialization: What Does Approval Mean?

Featured Talk:

• FDA CBER Director Wilson Bryan, M.D.: Regenerative Medicine Advanced Therapy (RMAT) Designation

Panels:

• Spotlight: Tissue Engineering
• Navigating Regenerative Medicine Technology Assessment and Reimbursement in North America and Europe
• Gene Therapy: Building the Gene Medicine Pipeline Through Next-Generation Technologies
• The Gene Editing Challenge: Validating Platform Technologies
• Accelerating Regulatory Development of Advanced Therapy Medicine Products for Patients in Need
• Spotlight: Financing the Cell and Gene Therapy Sector
• iPSCs for Therapeutic Applications

Workshops:

• Doing Business in Japan: Beyond Japan's Regulatory Renovation
• Manufacturing Gene Medicines
• Development of Cellular Therapies
• Health Technology Assessment
• Helping Your Cell Therapy Go Global
• Logistics, Automation and Standards

Throughout the two-day Partnering Forum, event participants can also attend presentations by more than 65 prominent publicly traded and emerging private companies, highlighting clinical and commercial progress in cell therapy, gene and gene-modified cell therapy, tissue engineering, biomaterials and more. In addition to their presentations, representatives from these organizations will also be available for one-on-one partnering opportunities throughout the conference.